With regard to radioligand therapy, the 2 most promising GRPR ligands, 68Ga-RM2 and 68Ga-NeoBOMB1, present some disadvantages: 68Ga-RM2 suffers from rapid metabolic degradation (17), which is why tumor accumulation and tumor dose for 177Lu-RM2 are likely limited as well—especially important in the context of radioligand therapy. The gene discussed is GRPR; the disease is neoplasm.